Sanofi MS Drug Clears Key Study While Failing in Two Others (1)

Sanofi succeeded in treating a challenging form of multiple sclerosis, offering a path to market for an experimental drug even as it failed to impress in two similar studies that tested its efficacy against that of an older medicine.

Tolebrutinib delayed the progression of disability in people with a progressive form of MS, an autoimmune disease, compared with those who received a placebo in the late-stage trial, the French company said in a statement Monday. There are currently no approved therapies for that group of MS patients, it said.

However, the drug failed to outperform Sanofi’s older therapy Aubagio when ...